Company to Initiate First-ever U.S. Clinical Investigation of iPSC-derived Cell Product
FT500 to be Featured in Oral Presentation on Monday, December 3 at ASH Annual Meeting
SAN DIEGO, Nov. 30, 2018 — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. [Read more…]